Patrick Spencer on Preparing Patients with Multiple Myeloma for Daratumumab Treatment
Patrick Spencer, RN, OCN provides important points to cover when counseling a patient with multiple myeloma receiving treatment with daratumumab.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
